9 results about "Buccal use" patented technology

The invention pertains to a natural chewing gum with nicotine (20) comprising a natural gum base (30) and active substance nicotine (34, 36, 38). The natural gum base (30) includes components or ingredients such as a gum base made of chicle with gum arabic or acacia, heat mixed with nicotine (34, 36, 38) in specific quantities. The chewing gum (20) is designed to administer nicotine during buccal use (70) up to 30 minutes while quickly releasing nicotine substance the first 5 minutes. The gum base (30) is covered with a glazing layer (40) with flavors (42) such as mint, strawberry, and taste enhancers with natural ingredients (44) such as xylitol, stevia, glycerin; beet powder, or spirulina, or a combination. A method for manufacturing the natural chewing gum (20) is disclosed, involving manufacturing of the gum base (100), addition of nicotine (200), manufacturing of the glazing mix (300), a glazing process (400), before packaging (500).

A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.

The present invention relates to a mucoadhesive layer for buccal administration of an active pharmaceutical ingredient (API), and to a method of preparing such mucoadhesive layer. Moreover, the present invention also relates to a mucoadhesive film comprising a mucoadhesive layer for buccal administration of an active pharmaceutical ingredient, and to a method of preparing such mucoadhesive film.

The present disclosure provides pouched products that include an outer water-permeable pouch defining a cavity; and a composition adapted for oral use situated within the cavity, the composition including at least one water-soluble component, a substantially spherical filler component in an amount of about 60% or more by dry weight of the composition, and water in an amount of about 30% or less by weight of the composition, wherein the average particle size of the substantially spherical filler component is about 350 microns to about 650 microns.

A dispersible solid pharmaceutical composition buccal dosage form is provided that results in a better pharmacokinetic profile in conjunction with a reduced incidence of adverse side effects and may be administered under fasting conditions. The buccal dosage form may include misoprostol or a pharmaceutically acceptable salt thereof, one or more disintegrants, lubricants, diluents, and optionally one or more other excipients (including but not limited or antioxidant, color, or flavor). The buccal dosage form may have a hardness of about 6 pK to about 10 pK, allows administration non-orally, namely buccally; disintegration or dispersion in less than about 60 seconds; and has a greater than about 80 percent dissolution at 15 minutes.

The present invention relates to the formulation of innovative pharmaceutical compositions for buccal use for use in the treatment and prevention of mucocutaneous diseases of the oral cavity. Said pharmaceutical compositions are able to resist salivary re-washing and have a high substantivity on the oral mucous membranes, obtaining a massive topical effect with the minimum possible systemic assimilation.

The present invention relates to the use of methylcellulose as a humectant in a pouch substrate and to a pouch for oral use comprising a pouch substrate wherein the pouch substrate comprises one or more carriers, one or more active ingredients and methylcellulose having a 5 viscosity at 20 DEG C of from about 200 to about 10000 cP at a concentration of 2% w / v.

We provide bite blocks, medical structures for protecting teeth. [Solution] The bite block of the present invention comprises a tooth protection member 11 having a perforation and a sleeve 12 provided on the front side of the tooth protection member and communicating with the perforation, wherein the sleeve communicates with the perforation, allowing for the insertion of an endotracheal tube and entry into the user's oral cavity. When in use, the tooth protection member is positioned between the user's upper and lower jaws and is placed in the user's mouth and bitten, preventing the user's teeth from moving or breaking in the event of a reflexive teeth clenching.